CDRE

Company Overview — What Does Cadre Holdings, Inc. Do?

Cadre Holdings, Inc. manufactures and distributes safety and survivability equipment that provides protection to users in hazardous or life-threatening situations in the United States and internationally. The company operates in two segments, Products and Distribution. It primarily provides body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brands; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective and law enforcement equipment comprising communications gear, forensic and investigation products, firearms cleaning solutions, and crowd control products. The company also offers third-party products, such as uniforms, optics, boots, firearms, and ammunition. It serves first responders, such as state and local law enforcement, fire and rescue, explosive ordnance disposal technicians, emergency medical technicians, fishing, and wildlife enforcement and departments of corrections, as well as federal agencies including the U.S. Department of State, U.S. Department of Defense, U.S. Department of Interior, U.S. Department of Justice, U.S. Department of Homeland Security, U.S. Department of Corrections, and various foreign government agencies. The company was founded in 1964 and is headquartered in Jacksonville, Florida. Cadre Holdings, Inc. (CDRE) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Warren B. Kanders and employs approximately 2,240 people. With a market capitalization of $1.4B, CDRE is one of the notable companies in the Healthcare sector.

Cadre Holdings, Inc. (CDRE) Stock Rating — Reduce (April 2026)

As of April 2026, Cadre Holdings, Inc. receives a Reduce rating with a composite score of 43.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CDRE ranks #3,179 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cadre Holdings, Inc. ranks #477 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CDRE Stock Price and 52-Week Range

Cadre Holdings, Inc. (CDRE) currently trades at $32.65. The stock lost $0.75 (2.2%) in the most recent trading session. The 52-week high for CDRE is $48.76, which means the stock is currently trading -33.0% from its annual peak. The 52-week low is $27.07, putting the stock 20.6% above its annual trough. Recent trading volume was 197K shares, suggesting relatively thin trading activity.

Is CDRE Overvalued or Undervalued? — Valuation Analysis

Cadre Holdings, Inc. (CDRE) carries a value factor score of 59/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 36.95x, compared to the Healthcare sector average of 23.63x — a premium of 56%. The price-to-book ratio stands at 4.19x, versus the sector average of 2.75x. The price-to-sales ratio is 2.41x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, CDRE trades at 25.45x EV/EBITDA, versus 6.34x for the sector.

Overall, CDRE's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Cadre Holdings, Inc. Profitability — ROE, Margins, and Quality Score

Cadre Holdings, Inc. (CDRE) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 11.3%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 4.7% versus the sector average of -33.1%.

On a margin basis, Cadre Holdings, Inc. reports gross margins of 40.8%, compared to 71.5% for the sector. The operating margin is 9.2% (sector: -66.1%). Net profit margin stands at 6.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 8.0% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

CDRE Debt, Balance Sheet, and Financial Health

Cadre Holdings, Inc. has a debt-to-equity ratio of 142.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.50x, indicating strong short-term liquidity. Cash and equivalents stand at $151M.

CDRE has a beta of 0.91, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Cadre Holdings, Inc. is 50/100, reflecting average volatility within the normal range for its sector.

Cadre Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cadre Holdings, Inc. reported revenue of $552M and earnings per share (EPS) of $1.08. Net income for the quarter was $36M. Gross margin was 40.8%. Operating income came in at $52M.

In FY 2025, Cadre Holdings, Inc. reported revenue of $610M and earnings per share (EPS) of $1.08. Net income for the quarter was $44M. Gross margin was 42.5%. Revenue grew 7.5% year-over-year compared to FY 2024. Operating income came in at $67M.

In Q3 2025, Cadre Holdings, Inc. reported revenue of $156M and earnings per share (EPS) of $0.27. Net income for the quarter was $11M. Gross margin was 42.7%. Revenue grew 42.5% year-over-year compared to Q3 2024. Operating income came in at $19M.

In Q2 2025, Cadre Holdings, Inc. reported revenue of $157M and earnings per share (EPS) of $0.30. Net income for the quarter was $12M. Gross margin was 40.9%. Revenue grew 8.9% year-over-year compared to Q2 2024. Operating income came in at $15M.

Over the past 8 quarters, Cadre Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $144M to $552M. Investors analyzing CDRE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CDRE Dividend Yield and Income Analysis

Cadre Holdings, Inc. (CDRE) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CDRE Momentum and Technical Analysis Profile

Cadre Holdings, Inc. (CDRE) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 30/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CDRE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cadre Holdings, Inc. (CDRE) ranks #477 out of 838 stocks based on the Blank Capital composite score. This places CDRE in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CDRE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CDRE vs S&P 500 (SPY) comparison to assess how Cadre Holdings, Inc. stacks up against the broader market across all factor dimensions.

CDRE Next Earnings Date

No upcoming earnings date has been announced for Cadre Holdings, Inc. (CDRE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CDRE? — Investment Thesis Summary

The quantitative profile for Cadre Holdings, Inc. suggests caution.

In summary, Cadre Holdings, Inc. (CDRE) earns a Reduce rating with a composite score of 43.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CDRE stock.

Related Resources for CDRE Investors

Explore more research and tools: CDRE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CDRE head-to-head with peers: CDRE vs AZN, CDRE vs SLGL, CDRE vs VMD.